Accidental ten times overdose administration of recombinant human erythropoietin (rh-EPO) up to 318,000 units a day in acute myocardial infarction: Report of two cases

被引:9
作者
Shin, DH [1 ]
Kwon, YI [1 ]
Choi, SI [1 ]
Park, US [1 ]
Lee, J [1 ]
Shin, JH [1 ]
Lee, JU [1 ]
Kim, SG [1 ]
Kim, JH [1 ]
Lim, HK [1 ]
Lee, BH [1 ]
Kim, KS [1 ]
机构
[1] Hanyang Univ, Coll Med, Div Cardiol, Seoul 133791, South Korea
关键词
D O I
10.1111/j.1742-7843.2006.pto_306.x
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The cytokine erythropoietin protects the heart from ischaemic injury, in part by preventing apoptosis. But appropriate dose of erythropoietin for the protection of injured heart has not been studied. While we were researching the cardiac protective effects of erythropoietin in acute myocardial infarction, we experienced two cases of accidental nearly ten times overdose administration of erythropoietin up to 318,000 units instead of 33,000 units on the second day of three scheduled days of treatment. So a total of 384,000 units of erythropoietin were administered during three days. In case 1, the ALT level soared up to 386 U/l on the second day of administration and decreased slowly. It was back to normal state 3 months later. The AST level increased slowly up to 391 U/l and normalized 3 months later. Haemoglobin level was elevated up to 15.7 g/dl (14.7 g/dl at admission) and, 3 months later, normalized to 14.8 g/dl. In case 2, the ALT level was elevated up to 98 U/l on the second day of administration and decreased slowly. Three months later, the ALT level was normalized. The AST level also increased slowly up to 71 U/l and normalized 3 months later. Haemoglobin level was elevated up to 15.6 g/dl (13.8 g/dl at admission) and, 3 months later, normalized to 13.6 g/dl. In these two cases reported, these patients, even after massive overdose, tolerated it relatively well and the only side-effects we found were elevated liver enzyme and haemoglobin levels.
引用
收藏
页码:222 / 224
页数:3
相关论文
共 9 条
[1]
An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection [J].
Bogoyevitch, MA .
CARDIOVASCULAR RESEARCH, 2004, 63 (02) :208-216
[2]
RECOMBINANT ERYTHROPOIETIN OVERDOSE [J].
BROWN, KR ;
CARTER, W ;
LOMBARDI, GE .
AMERICAN JOURNAL OF EMERGENCY MEDICINE, 1993, 11 (06) :619-621
[3]
Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling [J].
Calvillo, L ;
Latini, R ;
Kajstura, J ;
Leri, A ;
Anversa, P ;
Ghezzi, P ;
Salio, M ;
Cerami, A ;
Brines, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (08) :4802-4806
[4]
A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury [J].
Fiordaliso, F ;
Chimenti, S ;
Staszewsky, L ;
Bai, A ;
Carlo, E ;
Cuccovillo, I ;
Doni, M ;
Mengozzi, M ;
Tonelli, R ;
Ghezzi, P ;
Coleman, T ;
Brines, M ;
Cerami, A ;
Latini, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (06) :2046-2051
[5]
Maiese K, 2005, JAMA-J AM MED ASSOC, V293, P1858, DOI 10.1001/jama.293.15.1858-b
[6]
Erythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency: Case report and review of the literature [J].
Novak, BL ;
Force, RW ;
Mumford, BT ;
Solbrig, RM .
PHARMACOTHERAPY, 2003, 23 (02) :265-269
[7]
Effect of erythropoietin on cardiovascular diseases [J].
Sunder-Plassmann, G ;
Hörl, WH .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (04) :S20-S25
[8]
Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway [J].
Tramontano, AF ;
Muniyappa, R ;
Black, AD ;
Blendea, MC ;
Cohen, I ;
Deng, LL ;
Sowers, JR ;
Cutaia, MV ;
El-Sherif, N .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 308 (04) :990-994
[9]
Erythropoietin in cardiovascular diseases [J].
van der Meer, P ;
Voors, AA ;
Lipsic, E ;
van Gilst, WH ;
van Veldhuisen, DJ .
EUROPEAN HEART JOURNAL, 2004, 25 (04) :285-291